Châtillon, France – 30th May 2018 – TRIBVN Healthcare announces its commercial development in Europe and Canada.
TRIBVN Healthcare announces the recruitment of two business development managers in Europe and Canada.
TRIBVN Healthcare has been a major player in the bio-pathology imaging market for over 20 years and has developed high-performance and innovative software for digital pathology. CaloPix, its digital microscopy station allows to manage, read and analyze images in a daily workflow. TeleSlide, a collaborative web solution, allows to share digital slides for educational or telemedicine activities. These solutions integrate the latest innovations in terms of IT architecture and algorithms. They are perfectly suitable to an extensive use by our customers.
After winning several significant contracts in Europe and Canada, both in clinical and research, TRIBVN Healthcare has identified many development opportunities and decided to strengthen its commercial capacity to seize them.
• Irene Meliciani joined TRIBVN Healthcare in January 2018. Based in Munich, Germany, she holds a degree in biotechnology and a PhD in computational biochemistry from the Karlsruhe Institute of Technology in Germany. She did a post-doctorate at the Biomedical Research Park of Barcelona and has a strong commercial experience. She is now responsible for business development for the Pharma & Biotech segment in Europe.
• Pascal Tessier is based in Montreal and joined the company in April 2018. Pascal is an experienced salesman in the world of life sciences, medical diagnostics and health software, with a deep knowledge of the health sector. He is responsible for the business development of digital pathology in Canada for TRIBVN Healthcare.
« Both Irene and Pascal have extensive experience in the healthcare field, which allows them to play a key role in the company’s development strategy. Their expertise and energy will enable us to offer our solutions to more customers in Europe and Canada. These recruitments are a real asset for the company to improve our commercial presence and reflect our confidence in the development of digital pathology and in our ability to be one of the major players. » explains Jean-François Pomerol, TRIBVN Healthcare’s CEO.